According to The Insight Partners, the Human Vaccine Adjuvants Market is projected to grow from US$ 1,571.41 million in 2022 to US$ 4,489.23 million by 2030, registering a strong CAGR of 14.0% from 2022 to 2030. This significant growth highlights the increasing importance of adjuvants in enhancing vaccine efficacy and boosting immune responses, particularly in the United States, where robust...